Last reviewed · How we verify
Lipoplus + Omegaven
Lipoplus + Omegaven is a combination intravenous lipid emulsion that provides essential fatty acids and omega-3 polyunsaturated fatty acids for parenteral nutrition support.
Lipoplus + Omegaven is a combination intravenous lipid emulsion that provides essential fatty acids and omega-3 polyunsaturated fatty acids for parenteral nutrition support. Used for Parenteral nutrition in patients unable to receive adequate enteral nutrition, Critical illness and sepsis (omega-3 supplementation), Post-operative nutritional support.
At a glance
| Generic name | Lipoplus + Omegaven |
|---|---|
| Also known as | Lipoplus 20% BBraun Melsungen + Omegaven 10% Fresenius Kabi |
| Sponsor | General University Hospital, Prague |
| Drug class | Intravenous lipid emulsion |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Lipoplus is a lipid emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil that supplies energy and essential fatty acids. Omegaven is a fish oil-based lipid emulsion rich in omega-3 fatty acids (EPA and DHA) that provides anti-inflammatory benefits and supports cellular function. Together, they deliver balanced lipid nutrition with reduced omega-6 to omega-3 ratios, particularly beneficial in critical illness and parenteral nutrition.
Approved indications
- Parenteral nutrition in patients unable to receive adequate enteral nutrition
- Critical illness and sepsis (omega-3 supplementation)
- Post-operative nutritional support
Common side effects
- Hypertriglyceridemia
- Infusion site reactions
- Hepatic steatosis (with prolonged use)
- Allergic reactions
Key clinical trials
- Crossover Study on the Effect of Omegaven in Combination With Different Lipid Emulsions in Home Parenteral Nutrition (PHASE4)
- ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipoplus + Omegaven CI brief — competitive landscape report
- Lipoplus + Omegaven updates RSS · CI watch RSS
- General University Hospital, Prague portfolio CI